LSTA

LISATA THERAPEUTICS, INC. LSTA

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #2,819 of 2,925

Why it scores 15Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$0

Quarter to Jun 30

Net income

$-2.93M

Quarter to Jun 30

Free cash flow

$-2.65M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$4.11M total
VANGUARD CAPITAL MANAGEMENT LLC
$948.0K+2.6%
Yakira Capital Management, Inc.
$471.1KNew
Deeter Investments LLP
$404.2K-67.4%
CSS LLC/IL
$375.4K+78.4%
DELTEC ASSET MANAGEMENT LLC
$282.9K-7.6%
Rangeley Capital, LLC
$275.4K+8.0%
GEODE CAPITAL MANAGEMENT, LLC
$247.0K+2.5%
Virtu Financial LLC
$200.0K+39.3%
BlackRock, Inc.
$186.5K0.0%
VANGUARD FIDUCIARY TRUST CO
$166.5K+40.2%
GTS SECURITIES LLC
$102.7K-3.8%
STATE STREET CORP
$86.2K0.0%
JANE STREET GROUP, LLC
$63.7KNew
CITADEL ADVISORS LLC
$52.8K-31.4%
NORTHERN TRUST CORP
$52.8K+51.3%
JBF Capital, Inc.
$48.8K+8.4%
Cerity Partners LLC
$41.4K0.0%
BANK OF AMERICA CORP /DE/
$35.2K0.0%
HighTower Advisors, LLC
$34.1K0.0%
INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC
$16.8K0.0%
Founders Capital Management
$5.7K0.0%
Vanguard Global Advisers, LLC
$3.5K0.0%
Connective Capital Management, LLC
$3.5K0.0%
Tower Research Capital LLC (TRC)
$2.5K-7.5%
OSAIC HOLDINGS, INC.
$6800.0%
See all 33 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/LSTA

Earnings Per Share

13fpro.ai/company/LSTA

Loading ratio trend…

LSTA key financials by period

Reported revenue, net income and operating margin by fiscal year, from LISATA THERAPEUTICS, INC.'s annual filings on SEC EDGAR.

LISATA THERAPEUTICS, INC. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$170.0K$-16.6M—
FY 2024$1.0M$-20.0M—
FY 2016$35.3M$-32.7M-83.6%
FY 2015$22.5M$-81.0M—
FY 2014$17.9M$-54.9M—
FY 2013$14.7M$-39.0M—
Source: LSTA filings on SEC EDGAR →

LSTA insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About LISATA THERAPEUTICS, INC. (LSTA): stock profile, AI score and financials

LISATA THERAPEUTICS, INC. (LSTA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LSTA at 15.1/100 on a composite quality score built from its SEC filings, placing it at rank #2,819 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), LISATA THERAPEUTICS, INC. reports net income of $-2.9M, free cash flow of $-2.6M. Top institutional holders of LSTA by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, Yakira Capital Management, Deeter Investments LLP, based on the most recent SEC filings. LSTA trades on the Nasdaq exchange and files with the SEC under CIK 320017. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LSTA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for LISATA THERAPEUTICS, INC. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 320017 →